An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia.
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Bendamustine (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Expanded access; Registrational
- Acronyms BENDACT
- Sponsors Lundbeck Inc
- 18 Sep 2013 Actual end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Mar 2012 Planned initiation date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.